PHILADELPHIA and VANCOUVER, British Columbia — November 25, 2025 — Leads & Copy — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) will present positive biomarker and survival data across three clinical posters at the 2025 San Antonio Breast Cancer Symposium (SABCS®), according to a news release. The symposium is scheduled for December 9-12, 2025, at the Henry B. Gonzalez Convention Center in San Antonio, Texas.
According to Dr. William V. Williams, BriaCell’s President & CEO, the positive clinical data from the company’s Phase 2 study and differentiated biomarker findings from the Phase 3 program reinforce confidence in the pivotal Phase 3 study in metastatic breast cancer. He added that, together with BriaCell’s pipeline of novel off-the-shelf cell-based immunotherapies, the company remains committed to advancing breakthroughs in cancer immunotherapy to improve survival and clinical outcomes in cancer patients with unmet medical needs.
Dr. Miguel A. Lopez-Lago, BriaCell’s Chief Scientific Officer, noted that the biomarker data provides important insights into the mechanism of action of BriaCell’s novel immunotherapy with the goal of delivering more precisely targeted treatment options for oncologists, physicians, and patients.
The three poster presentations include:
- Late-Breaking Abstract Number: 3688; Presentation Number: PS1-13-22; Presentation Title: Impact of Prior Therapy, Genotype Matching, and Biomarkers in the Bria-ABC Phase 3 Trial; Poster Presentation Date/Time: Wednesday, December 10, 2025, 12:30 PM – 2:00 PM CST
- Late-Breaking Abstract Number: 3713; Presentation Number: PS1-13-23; Presentation Title: Survival Results of Phase II Bria-IMT Allogenic Whole Cell-Based Cancer Vaccine; Poster Presentation Date/Time: Wednesday, December 10, 2025, 12:30 PM – 2:00 PM CST
- Abstract Number: 1614; Presentation Number: PS2-09-03; Presentation Title: Th1-biased cytokine signatures as biomarkers of clinical benefit following SV-BR-1-GM cancer vaccination in breast cancer; Poster Presentation Date/Time: Wednesday, December 10, 2025, 5:00 PM – 6:30 PM CST
Copies of the abstracts and posters will be available at https://briacell.com/scientific-publications/.
The Phase 3 study of Bria-IMT+CPI is ongoing with an interim analysis expected in H1-2026. The Bria-IMT regimen has received Fast Track Designation from US FDA.
BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care.
William V. Williams, MD, is the President & CEO of BriaCell Therapeutics Corp. He can be reached at 1-888-485-6340 or info@briacell.com.
Investor Relations can be contacted at investors@briacell.com.
Source: BriaCell Therapeutics Corp.
Source: BriaCell Therapeutics Corp.
